Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Non-Current Deffered Revenue (2019 - 2021)

Fulcrum Therapeutics (FULC) has disclosed Non-Current Deffered Revenue for 3 consecutive years, with $1.7 million as the latest value for Q4 2021.

  • Quarterly Non-Current Deffered Revenue rose 1.88% to $1.7 million in Q4 2021 from the year-ago period, while the trailing twelve-month figure was $1.7 million through Dec 2021, up 1.88% year-over-year, with the annual reading at $1.7 million for FY2021, 1.88% up from the prior year.
  • Non-Current Deffered Revenue for Q4 2021 was $1.7 million at Fulcrum Therapeutics, up from $1.6 million in the prior quarter.
  • The five-year high for Non-Current Deffered Revenue was $6.0 million in Q4 2019, with the low at $1.5 million in Q1 2021.
  • Average Non-Current Deffered Revenue over 3 years is $2.4 million, with a median of $1.6 million recorded in 2020.
  • Peak annual rise in Non-Current Deffered Revenue hit 290.64% in 2020, while the deepest fall reached 72.57% in 2020.
  • Over 3 years, Non-Current Deffered Revenue stood at $6.0 million in 2019, then tumbled by 72.57% to $1.6 million in 2020, then grew by 1.88% to $1.7 million in 2021.
  • According to Business Quant data, Non-Current Deffered Revenue over the past three periods came in at $1.7 million, $1.6 million, and $1.7 million for Q4 2021, Q3 2021, and Q2 2021 respectively.